Balloon-occluded retrograde transvenous obliteration for gastric varices improves hepatic functional reserve in long-term follow-up.
balloon‐occluded retrograde transvenous obliteration
gastric varices
hepatic functional reserve
partial splenic embolization
prognosis
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
19
08
2021
revised:
22
10
2021
accepted:
01
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Balloon-occluded retrograde transvenous obliteration (BRTO) has been widely adopted for the management of gastric fundal varices (GVs). There are a few reports that BRTO leads to the improvement of mid-term and long-term hepatic functional reserve (HFR). We retrospectively investigated the long-term effect on HFR and prognosis among patients who had undergone BRTO for GVs. This single-center, retrospective study included 57successful patients out of 60 patients who underwent BRTO for GVs from December 2005 to September 2018. We examined the indicators of HFR (e.g., encephalopathy and ascites statuses, serum total bilirubin and albumin levels, % prothrombin time, and Child-Pugh and albumin-bilirubin [ALBI] scores) during 3 years of follow-up after BRTO. We analyzed survival using the Kaplan-Meier method and identified the independent prognostic factors via multivariate analyses. GVs disappeared in all patients who were successfully treated by BRTO. At 3 years after BRTO, serum albumin levels were significantly elevated (from 3.3 to 4.0 g/dL, BRTO for GVs has a favorable effect on long-term HFR.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Balloon-occluded retrograde transvenous obliteration (BRTO) has been widely adopted for the management of gastric fundal varices (GVs). There are a few reports that BRTO leads to the improvement of mid-term and long-term hepatic functional reserve (HFR). We retrospectively investigated the long-term effect on HFR and prognosis among patients who had undergone BRTO for GVs.
METHODS
METHODS
This single-center, retrospective study included 57successful patients out of 60 patients who underwent BRTO for GVs from December 2005 to September 2018. We examined the indicators of HFR (e.g., encephalopathy and ascites statuses, serum total bilirubin and albumin levels, % prothrombin time, and Child-Pugh and albumin-bilirubin [ALBI] scores) during 3 years of follow-up after BRTO. We analyzed survival using the Kaplan-Meier method and identified the independent prognostic factors via multivariate analyses.
RESULTS
RESULTS
GVs disappeared in all patients who were successfully treated by BRTO. At 3 years after BRTO, serum albumin levels were significantly elevated (from 3.3 to 4.0 g/dL,
CONCLUSION
CONCLUSIONS
BRTO for GVs has a favorable effect on long-term HFR.
Identifiants
pubmed: 34950775
doi: 10.1002/jgh3.12675
pii: JGH312675
pmc: PMC8674543
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1328-1334Informations de copyright
© 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Hepatol Res. 2018 Nov;48(12):1020-1030
pubmed: 29882396
United European Gastroenterol J. 2016 Feb;4(1):62-9
pubmed: 26966524
Surgery. 2001 Apr;129(4):414-20
pubmed: 11283531
Liver Cancer. 2019 Mar;8(2):121-129
pubmed: 31019902
J Gastroenterol Hepatol. 2010 Jun;25(6):1129-35
pubmed: 20594229
Intern Med. 2001 Aug;40(8):688-91
pubmed: 11518103
Hepatol Int. 2013 Mar;7(1):241-7
pubmed: 26201638
J Clin Exp Hepatol. 2017 Dec;7(4):300-304
pubmed: 29234193
Clin Gastroenterol Hepatol. 2005 Dec;3(12):1245-52
pubmed: 16361051
Radiographics. 2003 Jul-Aug;23(4):921-37; discussion 937
pubmed: 12853666
Cardiovasc Intervent Radiol. 2014 Apr;37(2):299-315
pubmed: 24091750
Dig Endosc. 2010 Jan;22(1):1-9
pubmed: 20078657
BMC Med Imaging. 2010 Jan 14;10:2
pubmed: 20074342
J Gastroenterol Hepatol. 1996 Jan;11(1):51-8
pubmed: 8672742
J Gastroenterol Hepatol. 2008 Nov;23(11):1702-9
pubmed: 18713295
J Vasc Interv Radiol. 2011 Mar;22(3):309-16; quiz 316
pubmed: 21353984
Semin Intervent Radiol. 2012 Jun;29(2):135-9
pubmed: 23729984
Gastroenterology. 1988 Aug;95(2):434-40
pubmed: 3391371
J Vasc Interv Radiol. 2005 Oct;16(10):1379-83
pubmed: 16221910
J Gastroenterol Hepatol. 2016 Nov;31(11):1844-1850
pubmed: 27003222
Radiology. 1999 May;211(2):349-56
pubmed: 10228513
J Vasc Interv Radiol. 2001 Mar;12(3):327-36
pubmed: 11287510
AJR Am J Roentgenol. 2012 Oct;199(4):721-9
pubmed: 22997361
AJR Am J Roentgenol. 2005 Apr;184(4):1340-6
pubmed: 15788621
J Gastroenterol Hepatol. 2014 May;29(5):1035-42
pubmed: 24372807
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Lancet. 1988 Aug 6;2(8606):340-1
pubmed: 2899760
Hepatogastroenterology. 1996 Sep-Oct;43(11):1212-7
pubmed: 8908553
J Vasc Interv Radiol. 2012 May;23(5):650-7
pubmed: 22459878
Kurume Med J. 2014;61(1-2):1-8
pubmed: 25420513
Am J Gastroenterol. 1997 Nov;92(11):2085-9
pubmed: 9362198
J Gastroenterol. 2007 Aug;42(8):663-72
pubmed: 17701130
J Gastroenterol Hepatol. 2003 Aug;18(8):934-42
pubmed: 12859723